On May 28, Mindray (300760.SZ) officially completed the first interim equity distribution for the years 2025 and 2026, distributing real cash dividends to all shareholders, with a total cash distribution of RMB 15.60 per 10 shares (including tax), amounting to a total dividend of approximately RMB 1.892 billion. The regular high proportion of dividends has been realized as promised, reaffirming the company's commitment to high shareholder returns and establishing itself as a benchmark for value dividends in the medical device industry.

This equity distribution consists of two parts: the profit distribution plan for 2025 distributes a cash dividend of RMB 3.10 per 10 shares, totaling RMB 376 million; the first interim profit distribution plan for 2026 distributes RMB 12.50 per 10 shares, totaling RMB 1.516 billion; the combined total of nearly RMB 1.9 billion in dividends has been realized, providing tangible returns to shareholders.

Since its listing on the ChiNext in 2018, Mindray has consistently prioritized investor returns, achieving dividends for eight consecutive years with steadily increasing dividend strength alongside operational growth. From 2018 to 2024, the company's cash dividend amount rose from RMB 1.216 billion to RMB 7.602 billion, an increase of over six times; the dividend payout ratio increased from 32.69% to 65.15%, achieving a dual increase in both dividend amount and ratio. Between 2023 and 2025, the company's dividend ratios are 60.72%, 65.15%, and 65.27%, respectively, continuing to rise and maintaining above 60%, further enhancing shareholder return levels. In addition, the company maintains multiple dividends each year, with the cumulative total of dividends and repurchases since its listing reaching RMB 37.336 billion, over six times the IPO fundraising scale, with dividends consistently occupying a high proportion of net profit attributable to the parent company, solidifying the foundation for investor returns.

Looking at mature capital markets globally, high-quality leading enterprises typically complete the transformation from growth stocks to value stocks. As a leading enterprise in the domestic medical device industry, Mindray has fulfilled the development characteristics of a quality enterprise. On the financial front, the company's operational resilience is evident, with revenue growing from RMB 13.753 billion in 2018 to RMB 33.282 billion in 2025, and net profit attributable to the parent company increasing from RMB 3.719 billion to RMB 8.135 billion, providing solid support for dividends through sustained and steady growth. In the first quarter of 2026, the company's revenue reached RMB 8.352 billion, with net profit attributable to the parent company at RMB 2.329 billion, continuously breaking through in overseas markets and high-end sectors, maintaining industry-leading gross and net profit margins, and ensuring robust profitability quality, laying a solid performance foundation for regular high dividends.

This substantial dividend of nearly RMB 1.9 billion, combined with the company's clearly defined shareholder return plan for 2025-2027, which states that under the condition of profit distribution, the annual cash dividend ratio will not be less than 65% of the distributable profit for that year, further confirms Mindray's long-term stable dividend fulfillment capability.

In the context of intensified competition in the medical device industry and differentiated industry patterns, Mindray demonstrates its confidence in its core business, innovative research and development, and global market expansion through continuous high-frequency dividend actions. Relying on the advantages of its three core segments: in vitro diagnostics, life information and support, and medical imaging, the company will continue to deepen its domestic and overseas markets, while allowing investors to share in the long-term development dividends of the enterprise through continuous shareholder returns alongside its own steady growth